Orphan Drug Amendment
Provision establishing U.S. disease incidence ceiling of 200,000 below which a drug treatment would be presumed an orphan, and thus eligible for tax credits under the law, is headed for White House following House and Senate passage during week ended Oct. 12. Amendment, part of Health Promotion and Disease Prevention Amendments of 1984 (S. 771), was agreed to by Sen. Hatch (R-Utah) and Rep. Waxman (D-Calif.) after Office of Management & Budget disagreed with FDA and the Treasury Dept. on the figure
You may also be interested in...
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.